Last updated: August 1, 2026
Diabeta is the former U.S. brand name for glyburide, also called glibenclamide, a second-generation sulfonylurea used to lower blood glucose in type 2 diabetes. Its U.S. commercial position has declined sharply because metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors and insulin products have displaced older sulfonylureas in treatment guidelines and prescribing practice. Diabeta has no meaningful new-drug exclusivity, no active innovation-led clinical development program, and limited standalone commercial value.
The remaining market is primarily generic glyburide, with demand concentrated in cost-sensitive treatment settings and selected pregnancy-related diabetes protocols. Glyburide use in gestational diabetes has also weakened because clinical guidance increasingly favors insulin and, in some settings, metformin.
What is Diabeta and what is glyburide used for?
Diabeta contains glyburide, an oral sulfonylurea that stimulates pancreatic beta cells to release insulin. The FDA-approved indication is adjunctive treatment, together with diet and exercise, for adults with type 2 diabetes mellitus who require pharmacologic glucose lowering.[1]
Diabeta is available in 1.25 mg, 2.5 mg and 5 mg tablets under the U.S. labeling historically associated with the brand. Micronized glyburide products use different tablet strengths and pharmacokinetic characteristics from nonmicronized formulations.[1]
| Attribute |
Diabeta |
| Active ingredient |
Glyburide |
| International name |
Glibenclamide |
| Drug class |
Second-generation sulfonylurea |
| Administration |
Oral tablet |
| Primary indication |
Type 2 diabetes |
| U.S. regulatory status |
Approved drug; brand availability has declined |
| Reference product status |
No meaningful remaining regulatory exclusivity |
| Main alternatives |
Metformin, insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, other sulfonylureas |
| Main safety issue |
Hypoglycemia |
| Other concerns |
Weight gain, prolonged hypoglycemia, reduced suitability in older adults and renal impairment |
Glyburide has a longer and more persistent hypoglycemia risk than some alternative agents. The American Geriatrics Society Beers Criteria identifies glyburide as a potentially inappropriate medication for many older adults because of prolonged hypoglycemia risk.[2]
What is the current FDA status of Diabeta?
Diabeta is an approved glyburide product, but the commercial market is largely generic. FDA labeling remains available for glyburide products, while active U.S. distribution depends on manufacturer-specific marketing and supply decisions.[1]
The FDA has not granted Diabeta a modern period of new chemical entity exclusivity. The product was approved before the current commercial environment for diabetes medicines developed, and its original brand protection has expired.
What is the Orange Book status of Diabeta?
The Orange Book is the FDA publication that lists approved drug products and, where applicable, patents and regulatory exclusivity. For a mature drug such as glyburide, the commercial issue is not remaining originator patent protection but the existence of approved generic alternatives.[3]
Diabeta does not have a commercially relevant patent barrier comparable with newer diabetes products such as semaglutide, tirzepatide, empagliflozin or dapagliflozin. Any patent listings associated with historical glyburide products would not create a practical barrier to generic entry in the current market.
What patents protect Diabeta and glyburide?
No active Diabeta patent estate is known to create material U.S. generic-entry risk. The original composition-of-matter and product patents associated with glyburide have expired. Generic glyburide products have therefore been available for many years.
| Patent issue |
Current commercial relevance |
| Glyburide active-ingredient patents |
Expired |
| Original Diabeta product protection |
Expired |
| Brand formulation exclusivity |
Expired |
| Method-of-use patents |
No known active barrier affecting ordinary type 2 diabetes use |
| Generic formulation patents |
May exist at the manufacturer level but do not protect the Diabeta brand |
| Manufacturing know-how |
Potentially relevant to quality and supply, but not a broad market-exclusion right |
| Biosimilar protection |
Not applicable; glyburide is a small-molecule drug |
Are formulation patents important for Diabeta?
Formulation differences can affect dissolution, bioavailability and tablet strength. Micronized glyburide products are an example of a formulation distinction, but formulation differences do not restore the original Diabeta market exclusivity.
A manufacturer could hold a patent covering a particular excipient system, manufacturing process or modified-release formulation. Such rights would generally apply only to the claimed product or process. They would not prevent all conventional immediate-release glyburide products from entering the market.
Are there active clinical trials for Diabeta?
Diabeta itself does not have an active originator-sponsored clinical development program. Glyburide and glibenclamide continue to appear in clinical research, but most studies relate to comparative diabetes treatment, gestational diabetes, neonatal hypoglycemia, preterm birth, neuroprotection or mechanistic research rather than a new Diabeta commercial indication.
ClinicalTrials.gov is the principal U.S. registry for identifying current interventional and observational studies.[4] Searches for glyburide and glibenclamide historically show a much larger body of completed research than ongoing commercial development.
What clinical research has evaluated glyburide?
Type 2 diabetes
Older trials evaluated glyburide as monotherapy and in combination with metformin or other glucose-lowering therapies. These studies established glyburide’s glucose-lowering activity but also documented hypoglycemia and weight gain. Current clinical development has shifted toward agents that reduce cardiovascular, kidney or weight-related risk.
Gestational diabetes
Glyburide has been studied as an alternative to insulin in gestational diabetes. Evidence has raised concerns about neonatal hypoglycemia, macrosomia and treatment failure compared with insulin. The American College of Obstetricians and Gynecologists has stated that glyburide is not preferred as a first-line alternative to insulin when insulin is indicated.[5]
Neonatal and pediatric research
Glibenclamide has been investigated in neonatal diabetes and other pediatric metabolic conditions. These studies generally concern off-label or specialized uses and do not support a broad Diabeta commercial expansion.
Neuroprotection and inflammation
Glyburide-related mechanisms have been studied in conditions involving the NLRP3 inflammasome and cerebral edema. These investigations are separate from the approved diabetes indication and have not created an approved Diabeta franchise.
When does Diabeta lose exclusivity?
Diabeta lost meaningful U.S. market exclusivity years ago. The relevant commercial event is therefore not a future patent-expiration date but continuing generic substitution and shrinking clinical demand.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Expired |
| Original patent protection |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
Not applicable to the core product |
| Reference-product exclusivity |
Expired |
| Generic entry |
Long established |
| Future loss-of-exclusivity event |
None with material market impact |
Which companies are challenging Diabeta?
Generic competition has already replaced most originator competition. The market has included multiple manufacturers and labelers of glyburide tablets, depending on product strength, formulation and distribution channel. The competitive process is based on abbreviated new drug applications rather than current Paragraph IV litigation against an active Diabeta patent estate.
Are there Paragraph IV challenges to Diabeta?
Paragraph IV litigation is not a material current risk category for Diabeta. A Paragraph IV certification challenges the validity, enforceability or infringement of a listed patent for a reference product.[6] Because glyburide has been genericized for an extended period and lacks a commercially meaningful Orange Book patent barrier, new Paragraph IV activity is unlikely to affect the market.
What patent litigation affects Diabeta?
No major current U.S. patent litigation is associated with the Diabeta brand or conventional glyburide tablets. Historical disputes, if any, would have limited relevance to present market access because generic glyburide has long been established.
The more relevant legal risks are ordinary pharmaceutical manufacturing and supply issues:
- Product-quality investigations
- Recalls
- Labeling compliance
- Good manufacturing practice enforcement
- Contract-manufacturing disputes
- Patent disputes involving a specific formulation or manufacturing process
- State substitution and reimbursement disputes
These issues can affect individual suppliers without restoring brand-level exclusivity.
How strong is the Diabeta patent estate?
The Diabeta patent estate is commercially weak because the core drug, conventional dosage forms and principal indication are no longer protected by enforceable exclusivity that could block generic competition.
| Patent-strength factor |
Assessment |
| Core composition patent |
Weak or expired |
| Conventional tablet protection |
Weak or expired |
| Method-of-use protection |
Limited commercial relevance |
| Formulation differentiation |
Possible at product level, not franchise level |
| Manufacturing barrier |
Moderate only where process complexity or quality controls matter |
| Litigation leverage |
Low |
| Generic-entry defense |
Low |
| Lifecycle-management potential |
Low without a new formulation or indication |
A new glyburide product would need to compete on cost, adherence, dosing, formulation, combination therapy or a differentiated clinical use. A simple relaunch of conventional Diabeta would have limited strategic value.
What is the market size for Diabeta and glyburide?
Public market-research reports generally combine glyburide with broader sulfonylurea or antidiabetic categories. Standalone Diabeta revenue is not consistently disclosed because the brand has limited commercial activity and generic glyburide sales are divided among manufacturers.
The market is best assessed through demand drivers rather than an originator-sales forecast.
Market drivers supporting glyburide
- Low acquisition cost
- Familiarity among some prescribers
- Broad availability of generic tablets
- Use in price-sensitive formularies
- Availability in multiple strengths
- Continued need for low-cost oral diabetes therapy in some health systems
Market drivers reducing glyburide demand
- Hypoglycemia risk
- Weight gain
- Reduced use in older adults
- Renal-function concerns
- Preference for metformin as initial therapy
- Use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiovascular, renal and weight benefits
- Greater caution regarding glyburide in gestational diabetes
- Formularies favoring alternative sulfonylureas or newer agents
The American Diabetes Association’s Standards of Care prioritize therapies according to glycemic efficacy, comorbidities, hypoglycemia risk, weight effects, cost and patient preference. Newer agents receive strong preference when cardiovascular, kidney or weight considerations are present.[7]
What is the glyburide market projection through 2030?
Glyburide is likely to remain a low-growth or declining mature generic market through 2030. The expected trajectory is volume erosion, price compression and continued supplier consolidation.
| Period |
Expected market direction |
Principal reason |
| 2025-2026 |
Stable to declining |
Generic substitution and lower prescribing |
| 2027-2028 |
Declining |
Continued migration to newer therapies |
| 2029-2030 |
Low-value residual market |
Persistence in cost-sensitive and selected legacy-use settings |
A reasonable strategic base case is a low-single-digit annual decline in glyburide demand through 2030, with steeper declines in high-income markets and slower erosion in low-cost treatment settings. Revenue may decline faster than volume because generic pricing remains competitive.
What could change the projection?
Upside factors include supply disruption involving competing drugs, renewed use in highly cost-constrained health systems, or clinical evidence supporting a narrowly defined population. Downside factors include stronger restrictions in older adults, more widespread use of GLP-1 and SGLT2 products, and additional generic supplier exits.
A new branded Diabeta investment would face substantial commercialization risk. The product lacks patent protection, has limited differentiation and competes against both inexpensive generic sulfonylureas and higher-value modern diabetes medicines.
How does Diabeta compare with competing diabetes drugs?
| Drug or class |
Primary advantage over glyburide |
Main disadvantage compared with glyburide |
| Metformin |
Low cost, established first-line role, limited hypoglycemia risk |
Gastrointestinal intolerance and contraindications in certain patients |
| Glimepiride |
Sulfonylurea alternative with continued use in some formularies |
Still carries hypoglycemia and weight-gain risk |
| DPP-4 inhibitors |
Low hypoglycemia risk and oral administration |
Higher cost and lower glucose-lowering potency |
| SGLT2 inhibitors |
Cardiovascular and kidney benefits in appropriate patients |
Higher cost and genitourinary adverse effects |
| GLP-1 receptor agonists |
Weight loss and strong glucose-lowering activity |
Injectable or higher-cost oral options, gastrointestinal effects |
| Insulin |
Highest glucose-lowering capacity |
Injection burden and hypoglycemia risk |
Glyburide’s strongest competitive attribute is price. Its weakest attributes are hypoglycemia risk, limited modern outcome benefits and lack of differentiation.
What generic launch risks exist for Diabeta?
Generic launch risk is already realized rather than prospective. New entrants would face a low regulatory barrier but unattractive economics.
Regulatory and commercial barriers
FDA approval of a conventional glyburide generic is less complex than approval of a new molecular entity, but the applicant must demonstrate pharmaceutical equivalence, bioequivalence where applicable, manufacturing compliance and quality consistency.[3] Commercial success would depend on securing formulary access, wholesaler distribution and reliable supply.
Manufacturing and intellectual-property barriers
Manufacturing barriers are modest for conventional tablets. They may increase for micronized products, specialized dissolution profiles or formulations requiring tighter control of particle size and content uniformity. These factors can create operational risk but do not provide broad market exclusivity.
What licensing deals involve Diabeta?
There is no major current licensing transaction driving the Diabeta market. Historical brand rights, manufacturing arrangements and distribution contracts may exist at the product level, but they do not represent a current innovation platform.
A licensing transaction involving glyburide would likely be commercially rational only if it included:
- A differentiated formulation
- A combination product
- A new delivery system
- A validated specialty indication
- Access to a low-cost manufacturing network
- Rights in a market with limited availability of competing therapies
Key Takeaways
- Diabeta is the former U.S. brand for glyburide, a mature second-generation sulfonylurea.
- The core patent and regulatory exclusivity position has expired.
- Generic glyburide has long been available, and Paragraph IV litigation is not a material current issue.
- No active originator-led clinical development program is driving Diabeta.
- Glyburide remains relevant mainly because of low cost and established availability.
- Clinical use is pressured by hypoglycemia, weight gain and the expansion of metformin, GLP-1 receptor agonists, SGLT2 inhibitors and insulin.
- Gestational-diabetes use has weakened as guidance increasingly favors insulin and, in selected settings, metformin.
- The market is expected to decline through 2030, with revenue likely falling faster than volume.
- A conventional Diabeta relaunch has weak patent protection and limited commercial differentiation.
- The strongest residual opportunity is a low-cost generic supply strategy, not an innovation-led branded franchise.
FAQs About Diabeta and Glyburide
Is Diabeta still available in the United States?
The Diabeta brand has limited commercial significance in the United States. Patients generally receive generic glyburide or an alternative glucose-lowering medicine.
Is glyburide the same as glibenclamide?
Yes. Glyburide is the U.S. name, while glibenclamide is widely used internationally for the same active ingredient.
Is Diabeta safer than metformin?
No broad safety advantage exists. Metformin generally has a lower hypoglycemia risk, while glyburide can cause prolonged hypoglycemia and weight gain.
Can glyburide be used during pregnancy?
Glyburide has been studied in gestational diabetes, but insulin is generally preferred when pharmacologic treatment is required. Clinical decisions depend on guideline, patient and obstetric factors.[5]
Does glyburide have biosimilar competition?
No. Glyburide is a chemically synthesized small-molecule drug, so its competitors are generics rather than biosimilars.
References
-
U.S. Food and Drug Administration. (n.d.). Diabeta (glyburide) prescribing information. FDA-approved labeling.
-
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
American College of Obstetricians and Gynecologists. (2018). ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstetrics & Gynecology, 131(2), e49-e64.
-
U.S. Food and Drug Administration. (n.d.). Applications covered by section 505(b)(2). FDA.
-
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes, 2025. Diabetes Care, 48(Supplement 1).
